Olema Oncology raises $54m for breast cancer drug candidate OP-1250
Olema Oncology, a California-based biopharma company focused on developing targeted therapies for women's cancers, has raised $54 million in a Series B financing round, which ... Read More
Ampio Pharmaceuticals begins phase 1 trial of Ampion for COVID-19 treatment
Ampio Pharmaceuticals has started a phase 1 clinical trial in the US for assessing its immunomodulatory anti-inflammatory agent Ampion as a five-day intravenous (IV) treatment ... Read More
BNT162 COVID-19 vaccine candidate : US govt signs $2bn supply deal with Pfizer and BioNTech
Pfizer and BioNTech have bagged a $1.95 billion deal with the US government for supplying 100 million doses of their jointly developed BNT162 COVID-19 vaccine ... Read More
Tenzing to acquire clinical-stage pharma company Reviva Pharmaceuticals
Tenzing Acquisition has agreed to acquire Reviva Pharmaceuticals, a California-based clinical-stage pharma company, focused on developing therapies for addressing unmet medical needs in the areas ... Read More
COV001 clinical trial results : Oxford vaccine ChAdOx1 nCoV-19 triggers strong immune response
COV001 clinical trial results : AstraZeneca and Oxford University said that interim results from the phase 1/2 COV001 clinical trial showed the ChAdOx1 nCoV-19 vaccine ... Read More
G42 Healthcare begins phase 3 trial of Sinopharm COVID-19 inactivated vaccine candidate in UAE
Sinopharm COVID-19 inactivated vaccine candidate : Chinese vaccine manufacturer Sinopharm CNBG has launched a phase 3 trial of its COVID-19 inactivated vaccine candidate, in collaboration ... Read More
Farxiga : AstraZeneca gets FDA fast track status for heart failure after MI
AstraZeneca has secured fast track designation for Farxiga (dapagliflozin) in the US for its use in reducing the risk of hospitalization for heart failure (hHF) ... Read More
Celltrion begins phase 1 human trial of COVID-19 antiviral antibody candidate
Celltrion Group, a South Korean pharma company, has launched a phase 1 human clinical trial of a potential antiviral antibody treatment for COVID-19 patients. The ... Read More
Chinese regulator accepts NDA of BeiGene’s pamiparib in ovarian cancer
BeiGene said that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted a new drug application (NDA) of ... Read More
Inozyme Pharma acquires Alexion’s ENPP1 gene deficiency program assets
Inozyme Pharma said that it has acquired Alexion Pharmaceuticals’ intellectual property and assets focused on ENPP1 gene deficiencies for an undisclosed price. The acquisition is ... Read More